A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer

PURPOSE: Orteronel (TAK-700) is a non-steroidal, selective, reversible inhibitor of 17,20-lyase. We evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Kazuhiro, Ozono, Seiichiro, Yamaguchi, Akito, Koike, Hidekazu, Matsui, Hiroshi, Nagata, Masao, Takubo, Takatoshi, Miyashita, Kana, Matsushima, Takafumi, Akaza, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305367/
https://www.ncbi.nlm.nih.gov/pubmed/25537627
http://dx.doi.org/10.1007/s00280-014-2654-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305367/
https://www.ncbi.nlm.nih.gov/pubmed/25537627
http://dx.doi.org/10.1007/s00280-014-2654-y

Ejemplares similares